Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($)	Sep. 30, 2018	Dec. 31, 2017
Current assets
Cash and cash equivalents	$ 170,219	$ 84,978
Other receivables	463,906	222,562
Note receivable - related party	44,859	44,859
Advances to CEN Biotech Ukraine LLC - related party	875,328	775,328
Property, plant and improvements, net	1,441,220	1,445,415
Deferred lease expense	176,482	217,210
Intangible assets, net	5,911,974	6,230,583
Total assets	9,083,988	9,020,935
Current liabilities
Accounts payable	219,692	104,828
Loans payable	10,122,412	9,981,883
Loans payable – related parties	1,062,727	838,923
Convertible notes payable	3,183,695	1,461,979
Convertible notes payable – related parties	1,098,000	2,210,313
Accrued interest	6,294,219	4,540,692
Accrued interest – related parties	858,965	592,901
Accrued expenses	371,177	295,874
Total current liabilities	23,210,887	20,027,393
Patent acquisition liability	620,000	5,000,000
Loans payable – related parties, less current portion	300,000	300,000
Convertible notes payable, less current portion	1,664,765	2,208,193
Convertible notes payable – related parties, less current portion	1,612,313	500,000
Total liabilities	27,407,965	28,035,586
Commitments and contingencies
Shareholders’ deficit
Common stock; unlimited authorized shares; 25,418,243 and 25,131,843 issued and outstanding as of September 30, 2018 and December 31, 2017, respectively. No par value.
Additional paid-in capital	14,169,809	9,110,041
Accumulated deficit	(32,493,786)	(28,124,692)
Total shareholders’ deficit	(18,323,977)	(19,014,651)
Total liabilities and shareholders’ deficit	$ 9,083,988	$ 9,020,935